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Scalp skin is physiologically very similar to non-palmoplan-
tar skin of the rest of the body, except for the very high
concentration of sebaceous glands (Giacometti, 1965). The
scalp environment, however, is much different in being cov-
ered by a thick fabric of hair. There are about 250 hair fibers
per cm2, which results, for a typical individual, in a hair sur-
face area of 50,000 cm2 relative to the scalp surface area of
600 cm2. Together, these parameters indicate the relative
inaccessibility of the scalp surface to targeted delivery of
actives; relatively low delivery efficiency in this protected
environment is an inherent challenge to achieving thera-
peutic benefits. This is especially true of the most patient-
friendly format—shampoos—since a rinsing step is involved
and the product cannot interfere with achieving desired
hair cosmetic benefits (compliance decreases dramatically
if hair cosmetics are poor). This places a large demand on
actives with high activity since delivery efficiency will be
inherently low as well as development of product phar-
macologies that maximize the benefit of the actives em-
ployed. This situation will be exemplified for the most
common scalp care therapeutic products, those designed
to treat dandruff and seborrheic dermatitis (D/SD) utilizing
anti-fungal actives to reduce Malassezia content on the
scalp.
The most common anti-fungal materials used in D/SD
scalp therapies include those based on rational chemical
design principles (ketoconazole, climbazole, pyrithione zinc
(PTZ), piroctone olamine and ciclopirox olamine) as well as
materials originating from indeterminate histories (selenium
sulfide, sulfur, coal tar, and salicylic acid). Because of the
aforementioned demands on activity due to challenging
delivery, only those materials with high intrinsic anti-fungal
activity should be considered as the basis for therapeutic
products. Based on measurement of minimal inhibitory
concentrations (MIC) against Malassezia, the most potent
materials from this group are pyrithione zinc, selenium
sulfide, climbazole, and ketoconazole (VanGerven and
Odds, 1995; Schmid and Ru¨hl-Ho¨rster, 1996).
For a formulated therapeutic product to be effective, a
potent active is a necessary but insufficient condition to
achieve activity. The way the active is delivered to the scalp
from the product formula, i.e., the product pharmacology, is
at least as strong a determinant of in-use activity as the
intrinsic active potency. For example, a comparison of clin-
ical flake-reduction efficacy of a variety 1% PTZ-based D/
SD shampoo products demonstrates a wide range of mag-
nitude of therapeutic benefits. Much of this variation is likely
due to the varying efficiency of delivery of PTZ, a particulate
active, to the scalp surface. Particulate PTZ delivery will be
affected by the physical size and shape of the particle (as
well as other formulation parameters, which will not be cov-
ered further here). Particles which are flat cover the scalp
surface more efficiently than those that are not. The particle
size is also critical as smaller particles provide better surface
coverage but are more difficult to retain on the scalp after
rinsing. These two opposing factors result in an optimum
size to maximize active delivery. Shampoo product formu-
lations utilizing PTZ particles optimized for delivery outper-
form those utilizing standard forms of the active (Fig 1). This
exemplifies one variable, beyond active potency, that must
be considered in selecting a therapeutic treatment.
Another important pharmacological variable that must be
considered is the role of the ‘‘non-functional’’ excipients in
Figure1
The impact of pyrithione zinc (PTZ) particle size on clinically ob-
served anti-dandruff efficacy from shampoo matrices. Sub-micron
particles are difficult to retain on the scalp after rinsing, whereas the
distribution of particles on the surface of the scalp (inset) improves as
the particles become smaller (note fungal cell target drawn to scale).
These off-setting factors result in an optimum particle size for efficacy
of 2.5 mm.Abbreviation: PTZ, pyrithione zinc
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the product formulation–it is well known that they can mod-
ulate, either positively or negatively, the activity of the drug
active. A specific example of how product excipients can
affect the activity of a scalp care formula is the addition of
zinc materials to PTZ-based therapeutic products. To un-
derstand the mechanism behind this effect requires some
understanding of a key component of the anti-fungal mech-
anism of the active ingredient PTZ itself.
Although the detailed understanding of the biological
mechanism of PTZ is beyond the scope of the article, it is
important to highlight the importance of the zinc component
of the metal-organic complex PTZ. PTZ is based on the
organic entity pyrithione (PT) where zinc ion (þ 2) forms a
salt with PT (1) in a 1:2 ratio. Evaluation of the in vitro anti-
fungal activity of the organic component (sodium pyrithione)
as well as a number of metal salts of this material (including
zinc, iron, nickel, and copper), demonstrates a range of over
three orders of magnitude (1000-fold) of potency. The zinc
salt (MIC of 8 ppm) is almost 10 times more potent than
sodium pyrithione (MIC of 64 ppm) alone and approximately
100 times more effective than, e.g., the iron salt (MIC of 500
ppm). This clearly highlights the importance of zinc to the
activity of PTZ and establishes the intact PTZ material as
the anti-fungal bio-active species. This conclusion becomes
the basis for understanding the effect of the formulation
containing a zinc excipient on the activity of PTZ.
PTZ, like all metal-organic complexes when in a liquid
medium, is governed by an equilibrium between the asso-
ciated zinc-pyrithione complex (i.e., PTZ) and dissociated
zinc and pyrithione components (Seymour and Bailey,
1981). Since PTZ is the bio-active species, dissociation
has negative consequences on efficacy. The greater the
dissociation, the less PTZ is present in the medium in a form
leading to anti-fungal activity. This is represented in the
equilibria summarized in Fig 2.
Zinc ion has essentially no anti-fungal activity of its own,
but enhances the anti-fungal activity of PTZ by over an or-
der of magnitude in in vitro evaluations (Fig 3). The mech-
anism involves shifting the equilibrium between PTZ and its
dissociated components. The basis for this effect is the
Figure 2
A summary of relevant pyrithione zinc (PTZ) equilibria governing realization of anti-fungal activity. (A) PTZ particles yield a soluble portion of
PTZ molecules, which penetrate the fungal cell membrane (green). (B) PTZ undergoes dissociative equilibria, which reduce the portion of the
material present in the bio-active complexed form. (C) The addition of an exogenous source of zinc ions (red) shifts the equilibria in the favor of the
complexed PTZ form, thereby increasing delivery to the fungal cells (red).
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well-established principle in chemical equilibria called
LeChaˆtelier’s Principle. Briefly, it states that a change im-
posed on a system at equilibrium shifts the equilibrium in a
way that reduces the effect of the change. In practical
terms, this means that the addition of a material which ap-
pears on one side of the equilibrium shifts the equilibrium in
the opposite direction. In the case of the PTZ equilibria,
added zinc forces the equilibrium towards the bio-active
PTZ complex. In effect, additional zinc is acting in the for-
mula to increase the bio-availability of PTZ to exert its anti-
fungal activity and is therefore considered a potentiated
PTZ formula.
Support for the mechanism comes from quantitation of
PTZ penetration into model mammalian cells. This can be
monitored by evaluating zinc levels within cells (modeling
delivery to Malassezia yeast cells) using fluorescent tech-
niques (Kim et al, 1999). Comparison of the zinc levels in
cells exposed to either PTZ or PTZ plus zinc, shows much
higher levels of intracellular PTZ (as zinc) in the case of
added zinc. This is the result of the effect additional zinc has
on increasing the bio-availability of PTZ as the equilibria in
Fig 2C demonstrate.
The zinc-enhanced PTZ activity observed in vitro and
understood in terms of increased bio-availability results in
increased performance in vivo in complex matrices as well.
Quantitation of in vivo Malassezia reduction from shampoo
matrices demonstrates PTZ formulation with zinc to be
more effective than PTZ formulations alone. This benefit
also translates to significantly improved clinical flake re-
duction from shampoos containing added zinc as an ex-
cipient.
In summary, whereas potent scalp actives must be se-
lected to achieve therapeutic activity, the product pharma-
cology must be considered in both the design and selection
of the product. Utilizing the example of PTZ-based D/SD
treatments, wide variability in clinical performance has been
observed. The origins can be understood in terms of how
efficiently the product delivers the active to the scalp surface
as well as the role that excipients play on modulating activity
of the product formulation containing the drug active.
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Figure 3
Kill rate microbiology evaluation of shampoo prototypes contain-
ing no active (placebo), pyrithione zinc (PTZ) alone, added zinc
alone and the combination. Zinc alone has no activity, but it potenti-
ates the activity of the PTZ formula.
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